文献速递肾移植急性肾损伤

成人肾移植受者中的产志贺毒素大肠埃希菌相关溶血性尿毒症综合征

Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome in Adult Kidney Transplant Recipients.
PubMed 文献 · Kidney Int Rep · 2025-08-11

这项法国15中心回顾性研究纳入2012至2022年确诊STEC-HUS的35例成人肾移植受者,年发病率估计为14.4/10万受者。6例为局限性肾内TMA、29例为系统性TMA,神经系统和心脏并发症仅见于系统性TMA。AKI和显著蛋白尿分别占89%和94%,移植物丢失率26%、死亡率9%。

要点

  • 成人肾移植受者STEC-HUS虽少见但严重,移植物丢失率26%、死亡率9%。
  • 移植后新发TMA无论有无前驱腹泻或仅局限性肾内表现,均应考虑STEC-HUS。
  • 神经系统和心脏并发症仅见于系统性TMA患者,需透析者均属系统性TMA。

核心结论

  • STEC-HUS是肾移植受者的严重并发症,显著损害移植物存活和总体生存。

研究设计与样本

  • 法国15个肾内科中心2012年1月至2022年4月的回顾性研究,纳入35例确诊STEC-HUS的成人肾移植受者。

主要发现

  • 年发病率估计为14.4例/10万肾移植受者。
  • 6例为局限性肾内TMA,29例为系统性TMA;神经系统和心脏并发症仅见于系统性TMA患者。
  • 移植至诊断中位时间3(1.2-6.2)年,诊断时平均年龄57±13岁。
  • AKI占89%,显著蛋白尿占94%;需要透析者占38%且均为系统性TMA。
  • 移植物丢失率26%,死亡率9%。

关键数值与推荐

  • 治疗包括阿奇霉素、依库珠单抗以及将钙调磷酸酶抑制剂(CNI)转换为贝拉西普。

临床怎么用

  • 对移植后新发TMA应系统排查STEC-HUS,无论有无前驱腹泻或仅表现为局限性肾内TMA。
  • 系统性TMA患者需警惕神经系统和心脏并发症,并关注需要透析的AKI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Shiga toxin (Stx)-producing Escherichia coli (E coli)-associated hemolytic uremic syndrome (STEC-HUS) is an acquired form of thrombotic microangiopathy (TMA) caused by food and waterborne infection. It remains the leading cause of acute renal injury (AKI) in children. In adults, STEC-HUS is less common but often more severe. Data on STEC-HUS in kidney transplant recipients (KTRs) are limited. METHODS: We conducted a retrospective study involving adult KTRs diagnosed with STEC-HUS between January 2012 and April 2022 across 15 French nephrology centers. We aimed to characterize the clinical, biological, and microbiological features of STEC-HUS in this population, its management, and outcomes. RESULTS: A total of 35 adult KTRs were included. The annual incidence was estimated at 14.4 cases per 100,000 KTRs. Six and 29 patients presented with localized intrarenal or systemic TMA, respectively. The median time from transplantation to STEC-HUS diagnosis was 3 (1.2-6.2) years and the mean age at diagnosis was 57 ± 13 years. Neurological and cardiac complications occurred exclusively in patients with systemic TMA. AKI and significant proteinuria were observed in 89% and 94% of patients, respectively. All patients requiring dialysis exhibited systemic TMA (38%). Treatment included azithromycin, eculizumab, and conversion from calcineurin inhibitors (CNIs) to belatacept. Graft loss and mortality rates were 26% and 9%, respectively. CONCLUSION: This study highlights that STEC-HUS represents a serious complication in KTRs, significantly impairing renal and overall survival. It should be systematically considered in cases of de novo posttransplant TMA, whether in the absence of prodromal diarrhea or in localized intra-renal presentations.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Mazloum M, Trémolières P, Baili N, et al. Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome in Adult Kidney Transplant Recipients. Kidney Int Rep. 2025. PMID: 41278354. doi:10.1016/j.ekir.2025.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。